Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy

Blood

Volumn 129, Issue 10, 2017, Pages 1397-1401

  Duncavage, Eric J ^a   Uy, Geoffrey L ^a   Petti, Allegra A ^a   Miller, Christopher A ^a   Lee, Yi Shan ^a   Tandon, Bevan ^a   Gao, Feng ^a   Fronick, Catrina C ^a   O'Laughlin, Michelle ^a   Fulton, Robert S ^a   Wilson, Richard K ^a   Jacoby, Meagan A ^a   Cashen, Amanda F ^a   Wartman, Lukas D ^a   Walter, Matthew J ^a   Westervelt, Peter ^a   Link, Daniel C ^a   DiPersio, John F ^a   Ley, Timothy J ^a   Welch, John S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; NUCLEOPHOSMIN; AZACITIDINE; TUMOR PROTEIN;

ACUTE MYELOID LEUKEMIA; BONE MARROW BIOPSY; COPY NUMBER VARIATION; DRUG RESPONSE; GENE FREQUENCY; GENE MUTATION; HUMAN; LETTER; LEUKOCYTE COUNT; LEUKOCYTOSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REMISSION; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; WHOLE GENOME SEQUENCING; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CELL; CLINICAL TRIAL; FEMALE; GENETICS; MALE; METABOLISM; MUTATION; PATHOLOGY;

AZACITIDINE; BLOOD CELLS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS;

EID: 85015152527     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-10-745273     Document Type: Letter

References (24)

1. Naqvi K, Jabbour E, Bueso-Ramos C, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011;118(17):4690-4693.
2. Font P, Loscertales J, Benavente C, et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol. 2013;92(1):19-24.
3. Senent L, Arenillas L, Lũno E, Ruiz JC, Sanz G, Florensa L. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica. 2013;98(4):568-575.
4. Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [published correction appears in J Clin Oncol. 2004;22(3):576]. J Clin Oncol. 2003;21(24):4642-4649.
5. Douglas DD, Risdall RJ. Bone marrow biopsy technic. Artifact induced by aspiration. Am J Clin Pathol. 1984;82(1):92-94.
6. Loken MR, Chu SC, Fritschle W, Kalnoski M, Wells DA. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom. 2009;76(1):27-36.
7. Font P, Loscertales J, Soto C, et al. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts. Ann Hematol. 2015;94(4):565-573.
8. Parmentier S, Schetelig J, Lorenz K, et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica. 2012;97(5):723-730.
9. Souto Filho JT, Loureiro MM, Pulcheri W, Morais JC, Nucci M, Portugal RD. Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy. Diagn Pathol. 2015;10:122.
10. Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell. 2014;25(3):379-392.
11. Ivey A, Hills RK, Simpson MA, et al; UK National Cancer Research Institute AML Working Group. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422-433.
12. Mohamedali AM, Gäken J, Ahmed M, et al. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia. 2015;29(9):1928-1938.
13. Tong WG, Sandhu VK, Wood BL, et al. Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. Haematologica. 2015;100(3):e97-e98.
14. Mohamedali AM, Alkhatabi H, Kulasekararaj A, et al. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. Blood. 2013;122(4):567-570.
15. Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627, quiz 3699.
16. Thol F, Bollin R, Gehlhaar M, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood. 2014;123(6):914-920.
17. Merlevede J, Droin N, Qin T, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7:10767.
18. Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023-2036.
19. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
20. Wong TN, Miller CA, Klco JM, et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood. 2016;127(7):893-897.
21. Griffith M, Miller CA, Griffith OL, et al. Optimizing cancer genome sequencing and analysis. Cell Syst. 2015;1(3):210-223.
22. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia [published correction appears in Nature. 2014;508(7496):420]. Nature. 2014;506(7488):328-333.
23. Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811-822.
24. Kwok B, Hall JM, Witte JS, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126(21):2355-2361.